Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00277-006-0173-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Truncated NS1 Influenza A Virus Induces a Robust Antigen-Specific Tissue-Resident T-Cell Response and Promotes Inducible Bronchus-Associated Lymphoid Tissue Formation in Mice.
Vaccines (Basel)
January 2025
Smorodintsev Research Institute of Influenza, The Ministry of Health of the Russian Federation, Saint-Petersburg 197022, Russia.
Background: Influenza viruses with truncated NS1 proteins show promise as viral vectors and candidates for mucosal universal influenza vaccines. These mutant NS1 viruses, which lack the N-terminal half of the NS1 protein (124 a.a.
View Article and Find Full Text PDFHigher Microbial Abundance and Diversity in Bronchus-Associated Lymphoid Tissue (BALT) Lymphomas than in Non-Cancerous Lung Tissues.
Cancer Res Treat
September 2024
Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Korea.
Article Synopsis
- The study investigates the microbiome in bronchus-associated lymphoid tissue (BALT) lymphoma, a rare type of MALT lymphoma in the lungs, using advanced sequencing methods.
- DNA was extracted from tumor tissues of BALT lymphoma patients to analyze bacterial profiles, revealing specific bacterial families that were more abundant in these tumors compared to non-cancerous lung tissues.
- Findings indicate that BALT lymphomas have a unique microbial composition and a distinct tumor microenvironment, providing new insights into the role of the microbiome in this type of lymphoma.
Long-term survival outcomes of 'watch and wait' in patients with bronchus-associated lymphoid tissue lymphoma: a multicenter real-world data analysis in Korea.
Ann Hematol
October 2024
Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81, Irwon-ro Gangnam-gu, Seoul, 06351, Korea.
Article Synopsis
- Bronchus-associated lymphoid tissue (BALT) lymphoma, or BALToma, is a rare type of cancer that often has a slow progression, leading many patients to adopt a watch-and-wait strategy instead of immediate treatment.
- A study of 67 patients from three hospitals in Korea found that patients who were just monitored or received minimal treatment had better long-term survival outcomes than those who underwent systemic chemotherapy: 10-year overall survival was 100% for the observation group compared to 71.7% for the chemotherapy group.
- Factors like having both lungs involved or extrapulmonary organ involvement were associated with worse progression-free survival, indicating that such patients may need closer monitoring and potentially more aggressive treatment options.
Regulation of pulmonary plasma cell responses during secondary infection with influenza virus.
J Exp Med
July 2024
University of Oxford, Kennedy Institute of Rheumatology, Oxford, UK.
During secondary infection with influenza virus, plasma cells (PCs) develop within the lung, providing a local source of antibodies. However, the site and mechanisms that regulate this process are poorly defined. Here, we show that while circulating memory B cells entered the lung during rechallenge and were activated within inducible bronchus-associated lymphoid tissues (iBALTs), resident memory B (BRM) cells responded earlier, and their activation occurred in a different niche: directly near infected alveoli.
View Article and Find Full Text PDFTreatment outcome, toxicity, and quality of life of patients with bronchus-associated lymphoid tissue lymphoma.
Leuk Lymphoma
June 2024
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, China.
The disease failure patterns and optimal treatment of bronchus-associated lymphoid tissue (BALT) lymphoma are unknown. This retrospective study involved 71 patients with primary BALT lymphoma who had received radiotherapy (RT), surgery, immunochemotherapy (IC), or observation. The median follow-up time was 66 months.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!